A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases-Reference-Cited by-同舟云学术

A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases

Published:2014-01 Issue:2 Volume:50 Page:277-289
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Aurilio Gaetano,Disalvatore Davide,Pruneri Giancarlo,Bagnardi Vincenzo,Viale Giuseppe,Curigliano Giuseppe,Adamoli Laura,Munzone Elisabetta,Sciandivasci Angela,De Vita Fernando,Goldhirsch Aron,Nolè Franco

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference66 articles.

1. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer;Rosen;Cancer,1977

2. Estrogen receptor levels in multiple biopsies from patients with breast cancer;Webster;Am J Surg,1978

3. Transformations related to the angular and the square root;Freeman;Ann Math Stat,1950

4. The inverse of the Freeman–Tukey double arcsine transformation;Miller;Am Stat,1978

5. Meta-analysis in clinical trials;DerSimonian;Control Clin Trials,1986

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of the mTOR signaling pathway can play an important role in breast cancer immunopathogenesis;Cell Biology International;2024-08-20

2. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease;Breast Cancer Research and Treatment;2024-08-01

3. Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors;Journal of Surgical Oncology;2024-07-22

4. Mexican breast cancer consensus. Management of advanced breast cancer;Gaceta Mexicana de Oncolog�a;2024-06-25

5. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review;Frontiers in Oncology;2024-06-17